title: Selective Retina Therapy in Patients With Chronic Central Serous Chorioretinopathy: A Pilot Study.
abstract: We evaluated visual outcomes, changes of maximum macular thickness (MMT) and subretinal fluid (SRF), and safety in patients with chronic central serous chorioretinopathy (CSC) after treatment with selective retina therapy (SRT). Retrospective cohort study of patients with chronic CSC presenting to a university-based hospital from January 2014 through January 2015 was conducted. A total of 12 eyes of 12 patients with chronic CSC lasting for at least 3 months was recruited. The follow-up period ranged from 3 to 12 months. Following evaluation of test spots at temporal arcades, SRT (Q-switched neodymium-doped yttrium lithium fluoride [Nd:YLF] laser; wavelength, 527 nm, pulse duration, 1.7 microsececond) was applied to the surrounding areas of leakage observed on fluorescein angiogram and/or pigment epithelial detachment (PED). Changes in best-correct visual acuity (BCVA), MMT, and SRF and macular sensitivity (MS) by microperimetry (MP) were evaluated. Eyes received treatment in a mean of 3.83 spots at the pulse energy of 65 to 90 μJ. Mean BCVA (logMAR) improved from 0.23 ± 0.12 at baseline to 0.14 ± 0.13 at 3 months. MMT decreased from 341.4 ± 85.5 μm at baseline to 236.0 ± 57.9 μm at 3 months. SRF completely resolved in 75% (9 eyes) at 3 months. Large PEDs (2 eyes) were flattened at 3 months. Retreatment was performed in 4 eyes. MP showed no evidence of scotoma around SRT-treated lesions. SRT treatment targeting the surrounding area of leakage point showed favorable visual and structural outcomes in chronic CSC patients without the risk of scotoma.
authors.affiliation: From the Department of Ophthalmology and Visual Science, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea (SK, YGP, JRK, YJR); Clinical Research Institute, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Daejeon, Republic of Korea (SK); and Medical Laser Center Lübeck GmbH, Lübeck, Germany (ES, DT-K, RB).
authors.forename: Seungbum
authors.initials: S
authors.lastname: Kang
authors.forename: Young Gun
authors.initials: YG
authors.lastname: Park
authors.forename: Jae Ryun
authors.initials: JR
authors.lastname: Kim
authors.forename: Eric
authors.initials: E
authors.lastname: Seifert
authors.forename: Dirk
authors.initials: D
authors.lastname: Theisen-Kunde
authors.forename: Ralf
authors.initials: R
authors.lastname: Brinkmann
authors.forename: Young Jung
authors.initials: YJ
authors.lastname: Roh
mesh_terms: D000328:Adult; D056833:Central Serous Chorioretinopathy / Q000473:pathology / Q000601:surgery*; D005260:Female; D006801:Humans; D053685:Laser Therapy / Q000379:methods*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012160:Retina / Q000473:pathology / Q000601:surgery; D012189:Retrospective Studies; D016896:Treatment Outcome; D014792:Visual Acuity
references.citation: Graefes Arch Clin Exp Ophthalmol. 2008 Oct;246(10):1373-8
references.pmid: 18546010
references.citation: Bull Soc Belge Ophtalmol. 2006;(302):51-69
references.pmid: 17265790
references.citation: Br J Ophthalmol. 2012 Mar;96(3):350-5
references.pmid: 21617156
references.citation: Retina. 2015 Mar;35(3):532-6
references.pmid: 25127050
references.citation: Graefes Arch Clin Exp Ophthalmol. 2006 Dec;244(12):1638-45
references.pmid: 16758179
references.citation: Ophthalmologe. 2006 Oct;103(10):850-5
references.pmid: 16937094
references.citation: Retina. 2011 Jan;31(1):119-26
references.pmid: 20890242
references.citation: Arch Ophthalmol. 1992 Dec;110(12):1786-92
references.pmid: 1463423
references.citation: Eye (Lond). 2014 Oct;28(10):1223-30
references.pmid: 25081286
references.citation: Br J Ophthalmol. 2000 Jan;84(1):40-7
references.pmid: 10611098
references.citation: Eye (Lond). 2012 Feb;26(2):307-14
references.pmid: 22079961
references.citation: Graefes Arch Clin Exp Ophthalmol. 2008 Sep;246(9):1235-9
references.pmid: 18523796
references.citation: Eye (Lond). 2009 Feb;23(2):488-9
references.pmid: 18344956
references.citation: Retina. 2003 Dec;23(6):752-63
references.pmid: 14707823
references.citation: Invest Ophthalmol Vis Sci. 2014 Dec 11;56(1):122-31
references.pmid: 25503454
references.citation: Cutan Ocul Toxicol. 2014 Jun;33(2):115-9
references.pmid: 23841829
references.citation: Clin Exp Ophthalmol. 2014 Dec;42(9):846-55
references.pmid: 24698550
references.citation: Graefes Arch Clin Exp Ophthalmol. 1986;224(4):321-4
references.pmid: 3710187
references.citation: Clin Exp Ophthalmol. 2013 Mar;41(2):201-14
references.pmid: 22788735
references.citation: Retina. 2003 Dec;23(6):820-46; quiz 895-6
references.pmid: 14707834
references.citation: Am J Ophthalmol. 2008 Jul;146(1):77-84
references.pmid: 18405876
references.citation: Acta Ophthalmol. 2009 Aug;87(5):511-6
references.pmid: 19508461
references.citation: Graefes Arch Clin Exp Ophthalmol. 2010 Sep;248(9):1263-72
references.pmid: 20393742
references.citation: Am J Ophthalmol. 2010 Feb;149(2):307-315.e2
references.pmid: 19896635
references.citation: Br J Ophthalmol. 2011 Jan;95(1):83-8
references.pmid: 20554506
references.citation: Graefes Arch Clin Exp Ophthalmol. 2010 May;248(5):651-8
references.pmid: 20024687
references.citation: Acta Ophthalmol. 2008 Mar;86(2):126-45
references.pmid: 17662099
references.citation: Arch Ophthalmol. 1999 Aug;117(8):1028-34
references.pmid: 10448745
references.citation: Graefes Arch Clin Exp Ophthalmol. 1994 Aug;232(8):473-6
references.pmid: 7926882